@article{scholars11523,
            year = {2019},
           pages = {219--226},
       publisher = {Elsevier B.V.},
         journal = {International Journal of Pharmaceutics},
             doi = {10.1016/j.ijpharm.2019.05.020},
            note = {cited By 28},
          volume = {565},
           title = {In vivo biocompatibility, pharmacokinetics, antitumor efficacy, and hypersensitivity evaluation of ionic liquid-mediated paclitaxel formulations},
          author = {Chowdhury, M. R. and Moshikur, R. M. and Wakabayashi, R. and Tahara, Y. and Kamiya, N. and Moniruzzaman, M. and Goto, M.},
            issn = {03785173},
             url = {https://www.scopus.com/inward/record.uri?eid=2-s2.0-85065414856&doi=10.1016\%2fj.ijpharm.2019.05.020&partnerID=40&md5=b60958bb8dae38009058c31b09a12caa},
        keywords = {paclitaxel; antineoplastic agent; cremophor; glycerol; ionic liquid; paclitaxel, allergic reaction; animal experiment; animal model; antineoplastic activity; area under the curve; Article; behavior change; biocompatibility; blood vessel permeability; cancer growth; cancer inhibition; cancer size; cell division; cell viability; complement activation; controlled study; drug delivery system; drug efficacy; drug elimination; drug formulation; drug retention; drug solubility; drug stability; female; follow up; high performance liquid chromatography; histamine release; hypersensitivity; in vitro study; in vivo study; mouse; nonhuman; particle size; priority journal; rate constant; survival time; animal; C57BL mouse; drug delivery system; drug hypersensitivity; intravenous drug administration; melanoma; skin tumor; tumor cell line, Administration, Intravenous; Animals; Antineoplastic Agents, Phytogenic; Cell Line, Tumor; Drug Delivery Systems; Drug Hypersensitivity; Female; Glycerol; Ionic Liquids; Melanoma; Mice, Inbred C57BL; Paclitaxel; Skin Neoplasms},
        abstract = {In order to prevent common hypersensitivity reactions to paclitaxel injections (Taxol), we previously reported an ionic liquid-mediated paclitaxel (IL-PTX)formulation with small particle size and narrow size distribution. The preliminary work showed high PTX solubility in the IL, and the formulation demonstrated similar antitumor activity to Taxol, while inducing a smaller hypersensitivity effect in in vitro cell experiments. In this study, the stability of the IL-PTX formulation was monitored by quantitative HPLC analysis, which showed that IL-PTX was more stable at 4 {\^A}oC than at room temperature. The in vivo study showed that the IL-PTX formulation could be used in a therapeutic application as a biocompatible component of a drug delivery system. To assess the in-vivo biocompatibility, IL or IL-mediated formulations were administered intravenously by maintaining physiological buffered conditions (neutral pH and isotonic salt concentration). From in vivo pharmacokinetics data, the IL-PTX formulation was found to have a similar systemic circulation time and slower elimination rate compared to cremophor EL mediated paclitaxel (CrEL-PTX). Furthermore, in vivo antitumor and hypersensitivity experiments in C57BL/6 mice revealed that IL-PTX had similar antitumor activity to CrEL-PTX, but a significantly smaller hypersensitivity effect compared with CrEL-PTX. Therefore, the IL-mediated formulation has potential to be an effective and safe drug delivery system for PTX. {\^A}{\copyright} 2019 Elsevier B.V.}
}